

IN THE CLAIMS:

1. (currently amended) A method of screening or testing for candidate anti-fungal compounds that impair

Candida albicans ATP(CTP):tRNA nucleotidyltransferase enzyme (CCA1) activity comprising:

- a) providing fungal *Candida albicans* CCA 1;
- b) providing one or more candidate compounds;
- c) contacting said CCA 1 with said one or more candidate compounds; and
- d) determining the ~~interaction of the candidate compound with said activity of CCA1~~
ability of the candidate compound to inhibit CCA1 activity.

2. (canceled)

3. (canceled)

4. (canceled)

5. (canceled)

6. (canceled)

7. (canceled)

8. (currently amended) A method of screening or testing for candidate anti-fungal compounds that impair *Candida albicans* ATP(CTP):tRNA nucleotidyltransferase enzyme (CCA1) activity comprising:

- a) providing a *C. albicans* cell wherein the cell expresses *Candida albicans* ATP(CTP):tRNA nucleotidyltransferase enzyme (CCA1) under the control of a heterologous promoter;
- b) providing one or more candidate compounds;

- c) contacting said *Candida albicans* cell(s) with said one or more candidate compounds;
- d) inducing said promoter; and
- e) determining ~~the effect of the candidate compound on CCA1~~
~~activity by assessing the effect on growth or viability of said cells whether the~~
~~candidate compound is a CCA1 inhibitor; and~~
- ~~f) comparing said activity to the activity of a sample of the *C. albicans* cell(s)~~
~~wherein said promoter is repressed.~~

9. (canceled)

10. (canceled)

11. (canceled)

12. (canceled)

13. (canceled)

14. (withdrawn) The method according to claim 18 wherein the fungal infection is a topical, mucosal or systemic fungal infection.

15. (withdrawn) The method according to claim 14 wherein the topical or mucosal fungal infection is caused by species of *Candida* or the systemic fungal infection is caused by species of *Candida* or *Aspergillus*.

16. (withdrawn) The method according to claim 18 wherein said compound impairs fungal CCA1 function to a greater extent than host CCA1 function.

17. (canceled)

18. (withdrawn) A method for the treatment or prevention of fungal infections in a host, which comprises administering to the host a therapeutically or prophylactically effective amount of a CCA1 inhibitor.

19. (withdrawn) A method for the treatment or prevention of fungal infections in a subject who is immunosuppressed, which comprises the step of administering to the subject a therapeutically or prophylactically effective amount of a CCA1 inhibitor.

20. (withdrawn) The method according to claim 19 wherein the fungal infection is a topical, mucosal or systemic fungal infection.

21. (withdrawn) The method according to claim 19 wherein the topical or mucosal fungal infection is caused by species of *Candida* or the systemic fungal infection is caused by species of *Candida* or *Aspergillus*.

22. (withdrawn) The method according to 19 wherein said compound impairs fungal CCA1 function to a greater extent than host CCA1 function.